Roche licenses GKA diabetes candidates to China's Hua Medicine
This article was originally published in Scrip
Executive Summary
The Shanghai, China-based drug development company Hua Medicine has signed a licensing agreement giving it exclusive development, manufacturing and global sales and marketing rights to a series of novel small molecule activators of the glucokinase enzyme developed by Roche, including RO5305553, which have the potential to lower elevated blood glucose levels in diabetes patients.